Document:

EX-4.3

 Exhibit 4.3 

 
  

THIRD SUPPLEMENTAL INDENTURE 

between 
 FULTON FINANCIAL
CORPORATION 
 AND 
 WILMINGTON
TRUST, NATIONAL ASSOCIATION 
 DATED AS OF March 3, 2020 

Third Supplement to Indenture dated as of November 17, 2014 

(Subordinated Debt Securities) 
  

 
  

 THIRD SUPPLEMENTAL INDENTURE, dated as of March 3, 2020 (this “Supplemental
Indenture”), between FULTON FINANCIAL CORPORATION, a Pennsylvania corporation (the “Corporation”), and WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee. 

RECITALS 
 WHEREAS, the
Corporation and the Trustee have entered into an Indenture dated as of November 17, 2014 (the “Base Indenture” and, as supplemented by this Supplemental Indenture, the “Indenture”), providing for the issuance
by the Corporation from time to time of its subordinated debt securities; 
 WHEREAS, Section 901(7) of the Base Indenture provides
that the Corporation and the Trustee may, without the consent of any Holder, enter into a supplemental indenture to establish the form or terms of Securities of any series as permitted by Section 201 and 301 thereof; 

WHEREAS, the Corporation desires to provide for the establishment of a new series of Securities pursuant to Sections 201 and 301 of the Base
Indenture, the form and substance of such Securities and terms, provisions and conditions thereof to be set forth as provided in the Indenture; 

WHEREAS, the Corporation deems it advisable to enter into this Supplemental Indenture for the purposes of establishing the terms of such
Securities and providing for the rights, obligations and duties of the Trustee with respect to such Securities; 
 WHEREAS, the execution
and delivery of this Supplemental Indenture has been authorized by a resolution of the Board of Directors of the Corporation; 
 WHEREAS,
the Corporation has requested that the Trustee execute and deliver this Supplemental Indenture and satisfy all requirements necessary to make this Supplemental Indenture a valid, legal and binding instrument in accordance with its terms, and to make
the Notes (as defined herein), when executed by the Corporation and authenticated and delivered by the Trustee, the valid, legal and binding obligations of the Corporation; and 

WHEREAS, all acts and things necessary have been done and performed to make this Supplemental Indenture enforceable in accordance with its
terms, and the execution and delivery of this Supplemental Indenture has been duly authorized in all respects. 
 NOW, THEREFORE, THIS
SUPPLEMENTAL INDENTURE WITNESSETH: For and in consideration of the premises and the purchase of the Notes by the Holders thereof, the Corporation and the Trustee covenant and agree, for the equal and proportionate benefit of all Holders of the
Notes, as follows: 

  
 1 

 ARTICLE ONE 

DEFINITIONS 
 Section 1.1
Definitions and Other Provisions of General Application. For all purposes of this Third Supplemental Indenture unless otherwise specified herein: 

(a)    All terms used in this Supplemental Indenture which are not otherwise defined herein shall have the meanings they
are given in the Base Indenture and include the plural as well as the singular; 
 (b)    The provisions of general
application stated in Sections 102 through 117 of the Base Indenture shall apply to this Supplemental Indenture, except that the words “herein,” “hereof,” “hereto” and “hereunder” and other words of similar
import refer to this Supplemental Indenture as a whole and not to the Base Indenture or any particular Article, Section or other subdivision of the Base Indenture or this Supplemental Indenture; and 

(c)    Section 101 of the Base Indenture is amended and supplemented, solely with respect to the Notes, by inserting the
following additional defined terms in their appropriate alphabetical positions: 
 “Administrative or Judicial Action” has
the meaning provided in the definition of “Tax Event.” 
 “Benchmark” means, initially, Three-Month Term
SOFR; provided that if the Calculation Agent determines on or prior to the Reference Time that a Benchmark Transition Event and its related Benchmark Replacement Date have occurred with respect to Three-Month Term SOFR or the then-current Benchmark,
then “Benchmark” means the applicable Benchmark Replacement. 
 “Benchmark Replacement” means the Interpolated
Benchmark with respect to the then-current Benchmark, plus the Benchmark Replacement Adjustment for such Benchmark; provided that if  (a) the Calculation Agent cannot determine the Interpolated Benchmark as of the Benchmark Replacement
Date or (b) the then-current Benchmark is Three-Month Term SOFR and a Benchmark Transition Event and its related Benchmark Replacement Date have occurred with respect to Three-Month Term SOFR (in which event no Interpolated Benchmark with
respect to Three-Month Term SOFR shall be determined), then 
 “Benchmark Replacement” means the first alternative set
forth in the order below that can be determined by the Calculation Agent as of the Benchmark Replacement Date: 
 (1) Compounded SOFR; 

  
 2 

 (2) the sum of: (a) the alternate rate that has been selected or recommended by the
Relevant Governmental Body as the replacement for the then-current Benchmark for the applicable Corresponding Tenor and (b) the Benchmark Replacement Adjustment; 

(3) the sum of: (a) the ISDA Fallback Rate, and (b) the Benchmark Replacement Adjustment; 

(4) the sum of: (a) the alternate rate that has been selected by the Calculation Agent as the replacement for the then-current Benchmark
for the applicable Corresponding Tenor, giving due consideration to any industry-accepted rate as a replacement for the then-current Benchmark for U.S. dollar-denominated floating rate securities at such time, and (b) the Benchmark Replacement
Adjustment. 
 “Benchmark Replacement Adjustment” means the first alternative set forth in the order below that can be
determined by the Calculation Agent as of the Benchmark Replacement Date: 
 (1) the spread adjustment, or method for calculating or
determining such spread adjustment (which may be a positive or negative value or zero), that has been selected or recommended by the Relevant Governmental Body for the applicable Unadjusted Benchmark Replacement; 

(2) if the applicable Unadjusted Benchmark Replacement is equivalent to the ISDA Fallback Rate, then the ISDA Fallback Adjustment; and 

(3) the spread adjustment (which may be a positive or negative value or zero) that has been selected by the Calculation Agent giving due
consideration to any industry-accepted spread adjustment or method for calculating or determining such spread adjustment, for the replacement of the then-current Benchmark with the applicable Unadjusted Benchmark Replacement for U.S.
dollar-denominated floating rate securities at such time. 
 “Benchmark Replacement Conforming Changes” means, with respect
to any Benchmark Replacement, any technical, administrative or operational changes (including changes to the definition of  “interest period,” timing and frequency of determining rates with respect to each interest period and making
payments of interest, rounding of amounts or tenors, and other administrative matters) that the Calculation Agent decides may be appropriate to reflect the adoption of such Benchmark Replacement in a manner substantially consistent with market
practice (or, if the Calculation Agent decides that adoption of any portion of such market practice is not administratively feasible or if the Calculation Agent determines that no market practice for use of the Benchmark Replacement exists, in such
other manner as the Calculation Agent determines is reasonably necessary). 

  
 3 

 “Benchmark Replacement Date” means the earliest to occur of the following
events with respect to the then-current Benchmark: 
 (1) in the case of clause (1) of the definition of  “Benchmark
Transition Event,” the relevant Reference Time in respect of any determination; 
 (2) in the case of clause (2) or (3) of the
definition of  “Benchmark Transition Event,” the later of (a) the date of the public statement or publication of information referenced therein and (b) the date on which the administrator of the Benchmark permanently or
indefinitely ceases to provide the Benchmark; or 
 (3) in the case of clause (4) of the definition of  “Benchmark Transition
Event,” the date of the public statement or publication of information referenced therein. 
 For the avoidance of doubt, for purposes
of the definitions of Benchmark Replacement Date and Benchmark Transition Event, references to the Benchmark also include any reference rate underlying the Benchmark (for example, if the Benchmark becomes Compounded SOFR, references to the Benchmark
would include SOFR). 
 For the avoidance of doubt, if the event giving rise to the Benchmark Replacement Date occurs on the same day as,
but earlier than, the Reference Time in respect of any determination, the Benchmark Replacement Date will be deemed to have occurred prior to the Reference Time for such determination. 

“Benchmark Transition Event” means the occurrence of one or more of the following events with respect to the then-current
Benchmark: 
 (1) if the Benchmark is Three-Month Term SOFR, (a) the Relevant Governmental Body has not selected or recommended a
forward-looking term rate for a tenor of three months based on SOFR, (b) the development of a forward-looking term rate for a tenor of three months based on SOFR that has been recommended or selected by the Relevant Governmental Body is not
complete or (c) the Corporation determines that the use of a forward-looking rate for a tenor of three months based on SOFR is not administratively feasible; 

(2) a public statement or publication of information by or on behalf of the administrator of the Benchmark announcing that such administrator
has ceased or will cease to provide the Benchmark, permanently or indefinitely, provided that, at the time of such statement or publication, there is no successor administrator that will continue to provide the Benchmark; 

(3) a public statement or publication of information by the regulatory supervisor for the administrator of the Benchmark, the central bank for
the currency of the Benchmark, an insolvency official with jurisdiction over the administrator for the Benchmark, a resolution authority with jurisdiction over the administrator for the Benchmark or a court or an entity with similar insolvency or
resolution authority over the administrator for the Benchmark, which states that the administrator of the Benchmark has ceased or will cease to provide the Benchmark permanently or indefinitely, provided that, at the time of such statement or
publication, there is no successor administrator that will continue to provide the Benchmark; or 

  
 4 

 (4) a public statement or publication of information by the regulatory supervisor for the
administrator of the Benchmark announcing that the Benchmark is no longer representative. 
 “Business Day” means
(A) each Monday, Tuesday, Wednesday, Thursday and Friday which is not a day on which banking institutions in New York are authorized or obligated by law or executive order to close, or (B) a day on which the corporate trust office of the
Trustee is not closed for business. 
 “Calculation Agent” means the agent appointed by the Corporation prior to the
commencement of the Floating Rate Period (which may include the Corporation or any of its Affiliates) to act in accordance with Section 2.4. 

“Compounded SOFR” means the compounded average of SOFRs for the applicable Corresponding Tenor, with the rate, or methodology
for this rate, and conventions for this rate being established by the Calculation Agent in accordance with: 
 (1) the rate, or methodology
for this rate, and conventions for this rate selected or recommended by the Relevant Governmental Body for determining compounded SOFR; provided that: 

(2) if, and to the extent that, the Calculation Agent determines that Compounded SOFR cannot be determined in accordance with clause
(1) above, then the rate, or methodology for this rate, and conventions for this rate that have been selected by the Calculation Agent giving due consideration to any industry-accepted market practice for U.S. dollar-denominated floating rate
securities at such time. 
 For the avoidance of doubt, the calculation of Compounded SOFR shall exclude the Benchmark Replacement
Adjustment (if applicable) and the spread of 270 basis points per annum. 
 “Corresponding Tenor” with respect to a
Benchmark Replacement means a tenor (including overnight) having approximately the same length (disregarding business day adjustment) as the applicable tenor for the then-current Benchmark. 

“DTC” means The Depository Trust Company. 

“Federal Reserve” has the meaning provided in the definition of “Tier 2 Capital Event.” 

“Federal Reserve Bank of New York’s Website” means the website of the Federal Reserve Bank of New York at
http://www.newyorkfed.org, or any successor source. 
 “Fixed Rate Interest Payment Date” has the meaning provided in
Section 2.4(a). 

  
 5 

 “Fixed Rate Period” has the meaning provided in Section 2.4(a). 

“Fixed Rate Regular Record Date” has the meaning provided in Section 2.4(a). 

“Floating Rate Interest Payment Date” has the meaning provided in Section 2.4(b). 

“Floating Rate Period” has the meaning provided in Section 2.4(b). 

“Floating Rate Regular Record Date” has the meaning provided in Section 2.4(b). 

“Interest Payment Date” has the meaning provided in Section 2.4(b). 

“interest period” means the period from and including the immediately preceding Interest Payment Date in respect of which
interest has been paid or duly provided for or, if no interest has been paid or duly provided for, from and including the Issue Date to, but excluding, the applicable Interest Payment Date or the Maturity Date or date of earlier redemption, if
applicable. 
 “Interpolated Benchmark” with respect to the Benchmark means the rate determined for the Corresponding Tenor
by interpolating on a linear basis between: (1) the Benchmark for the longest period (for which the Benchmark is available) that is shorter than the Corresponding Tenor, and (2) the Benchmark for the shortest period (for which the
Benchmark is available) that is longer than the Corresponding Tenor. 
 “ISDA Definitions” means the 2006 ISDA Definitions
published by the International Swaps and Derivatives Association, Inc. or any successor thereto, as amended or supplemented from time to time, or any successor definitional booklet for interest rate derivatives published from time to time. 

“ISDA Fallback Adjustment” means the spread adjustment (which may be a positive or negative value or zero) that would apply
for derivatives transactions referencing the ISDA Definitions to be determined upon the occurrence of an index cessation event with respect to the Benchmark for the applicable tenor. 

“ISDA Fallback Rate” means the rate that would apply for derivatives transactions referencing the ISDA Definitions to be
effective upon the occurrence of an index cessation date with respect to the Benchmark for the applicable tenor excluding the applicable ISDA Fallback Adjustment. 

“Issue Date” means March 3, 2020. 

“Maturity Date” has the meaning provided in Section 2.2. 

“Redemption Date” has the meaning provided in Section 2.5. 

  
 6 

 “Reference Time” with respect to any determination of the Benchmark means
(1) if the Benchmark is Three-Month Term SOFR, the time determined by the Calculation Agent after giving effect to the Three-Month Term SOFR Conventions, and (2) if the Benchmark is not Three-Month Term SOFR, the time determined by the
Calculation Agent after giving effect to the Benchmark Replacement Conforming Changes. 
 “Relevant Governmental Body”
means the Federal Reserve and/or the Federal Reserve Bank of New York, or a committee officially endorsed or convened by the Federal Reserve and/or the Federal Reserve Bank of New York or any successor thereto. 

“SOFR” means the secured overnight financing rate published by the Federal Reserve Bank of New York, as the administrator of
the Benchmark (or a successor administrator), on the Federal Reserve Bank of New York’s website. 
 “Tax Event” means
the receipt by the Corporation of an opinion of independent tax counsel to the effect that as a result of (a) an amendment to or change (including any announced prospective amendment or change) in any law or treaty, or any regulation
thereunder, of the United States or any of its political subdivisions or taxing authorities; (b) a judicial decision, administrative action, official administrative pronouncement, ruling, regulatory procedure, regulation, notice or
announcement, including any notice or announcement of intent to adopt or promulgate any ruling, regulatory procedure or regulation (any of the foregoing, an “Administrative or Judicial Action”); or (c) an amendment to or change
in any official position with respect to, or any interpretation of, an Administrative or Judicial Action or a law or regulation of the United States that differs from the previously generally accepted position or interpretation, in each case, which
change or amendment or challenge becomes effective or which pronouncement, decision or challenge is announced on or after the original issue date of the Notes, there is more than an insubstantial risk that interest payable by the Corporation on the
Notes is not, or, within 90 days of the date of such opinion, will not be, deductible by the Corporation, in whole or in part, for United States federal income tax purposes. 

“Term SOFR” means the forward-looking term rate based on SOFR that has been selected or recommended by the Relevant
Governmental Body. 
 “Term SOFR Administrator” means any entity designated by the Relevant Governmental Body as the
administrator of Term SOFR (or a successor administrator). 
 “Three-Month Term SOFR” means the rate for Term SOFR for a
tenor of three months that is published by the Term SOFR Administrator at the Reference Time for any interest period, as determined by the Calculation Agent after giving effect to the Three-Month Term SOFR Conventions. All percentages used in or
resulting from any calculation of Three-Month Term SOFR shall be rounded, if necessary, to the nearest one-hundred-thousandth of a percentage point, with 0.000005% rounded up to 0.00001%. 

  
 7 

 “Three-Month Term SOFR Conventions” means any determination, decision or
election with respect to any technical, administrative or operational matter (including with respect to the manner and timing of the publication of Three-Month Term SOFR, or changes to the definition of   “interest period,”
timing and frequency of determining Three-Month Term SOFR with respect to each interest period and making payments of interest, rounding of amounts or tenors, and other administrative matters) that the Calculation Agent decides may be appropriate to
reflect the use of Three-Month Term SOFR as the Benchmark in a manner substantially consistent with market practice (or, if the Calculation Agent decides that adoption of any portion of such market practice is not administratively feasible or if the
Calculation Agent determines that no market practice for the use of Three-Month Term SOFR exists, in such other manner as the Calculation Agent determines is reasonably necessary). 

“Tier 2 Capital Event” means the Corporation’s good faith determination that, as a result of (a) any amendment to,
or change in, the laws, rules or regulations of the United States (including, for the avoidance of doubt, any agency or instrumentality of the United States, including the Federal Reserve and other federal bank regulatory agencies) or any political
subdivision of or in the United States that is enacted or becomes effective after the original issue date of the Notes; (b) any proposed change in those laws, rules or regulations that is announced or becomes effective after the original issue
date of the Notes; or (c) any official administrative decision or judicial decision or administrative action or other official pronouncement interpreting or applying those laws, rules, regulations, policies or guidelines with respect thereto
that is announced after the original issue date of the Notes, there is more than an insubstantial risk that the Corporation will not be entitled to treat the Notes then outstanding as “Tier 2 Capital” (or its equivalent) for purposes of
the capital adequacy rules or regulations of the Board of Governors of the Federal Reserve System (the “Federal Reserve”) (or, as and if applicable, the capital adequacy rules or regulations of any successor appropriate federal
banking agency) as then in effect and applicable to the Corporation, for so long as any Notes are outstanding. 
 “Unadjusted
Benchmark Replacement” means the Benchmark Replacement excluding the Benchmark Replacement Adjustment. 
 ARTICLE TWO 

CREATION OF THE NOTES 

Section 2.1 Designation of Series. Pursuant to the terms hereof and Sections 201 and 301 of the Base Indenture, the Corporation
hereby creates a series of its subordinated debt securities designated as the “3.750% Fixed-to-Floating Rate Subordinated Notes due 2035” (the
“Notes”), which Notes shall be deemed “Securities” for all purposes under the Indenture. 

  
 8 

 Section 2.2 Form and Minimum Denomination of Notes. The definitive form of the
Notes shall be substantially in the form set forth in Exhibit A attached hereto, which is incorporated herein and made part hereof. The Notes shall bear interest and have such other terms as are stated in the form of definitive Notes or in
the Indenture. The Stated Maturity of the Notes shall be March 15, 2035 (the “Maturity Date”). The Notes shall be issued in denominations of $1,000 and integral multiples of $1,000 in excess thereof. 

Section 2.3 Initial Limit on Amount of Series. The Notes shall initially be limited to U.S. $175,000,000 in aggregate principal
amount, and may, upon the execution and delivery of this Supplemental Indenture or from time to time thereafter, be executed by the Corporation and delivered to the Trustee for authentication, and the Trustee shall thereupon authenticate and deliver
said Notes to or upon the delivery of a Corporation Order. Following the initial issuance of the Notes, the aggregate principal amount of Notes may be increased as provided in Section 1.8. 

Section 2.4 Interest. 

(a)    The Notes will bear interest at a fixed rate of 3.750% per annum from and including March 3, 2020 to, but
excluding, March 15, 2030 or earlier Redemption Date (the “Fixed Rate Period”). Interest accrued on the Notes during the Fixed Rate Period will be payable semi-annually in arrears on March 15 and September 15 of each
year, commencing on September 15, 2020 (each such date, a “Fixed Rate Interest Payment Date”). The last Fixed Rate Interest Payment Date shall be March 15, 2030, unless the Notes are earlier redeemed. The interest payable
during the Fixed Rate Period will be paid to each Holder in whose name a Note is registered at the close of business on the fifteenth day (whether or not a Business Day) immediately preceding the applicable Fixed Rate Interest Payment Date (each
such date, a “Fixed Rate Regular Record Date”). 
 (b)    The Notes will bear a floating interest rate
from, and including March 15, 2030, to, but excluding, the Maturity Date or earlier Redemption Date (the “Floating Rate Period”). The floating interest rate will be reset quarterly, and the interest rate for any Floating Rate
Period shall be equal to the then-current Three-Month Term SOFR plus 270 basis points for each quarterly interest period during the Floating Rate Period. During the Floating Rate Period, interest on the Notes will be payable quarterly in arrears on
March 15, June 15, September 15 and December 15 of each year commencing, on June 15, 2030 (each such date, a “Floating Rate Interest Payment Date” and, together with a Fixed Rate Interest Payment Date, an
“Interest Payment Date”). The interest payable during the Floating Rate Period will be paid to each Holder in whose name a Note is registered at the close of business on the fifteenth day (whether or not a Business Day) immediately
preceding the applicable Floating Rate Interest Payment Date (each such date, a “Floating Rate Regular Record Date”). Notwithstanding the foregoing, if Three-Month Term SOFR (or other applicable Benchmark) is less than zero, then
Three-Month Term SOFR (or other such Benchmark) shall be deemed to be zero. The Calculation Agent will provide the Corporation and the Trustee with the interest rate in effect on the Notes promptly after the Reference Time (or such other date of
determination for the applicable Benchmark). 

  
 9 

 (c)    The amount of interest payable on any Fixed Rate Interest Payment
Date during the Fixed Rate Period will be computed on the basis of a 360-day year consisting of twelve 30-day months to, but excluding, March 15, 2030, and, the
amount of interest payable on any Floating Rate Interest Payment Date during the Floating Rate Period will be computed on the basis of a 360-day year on the basis of the actual number of days elapsed. The
Corporation or the Calculation Agent, as applicable, shall calculate the amount of interest payable on any Interest Payment Date and the Trustee shall have no duty to confirm or verify any such calculation. In the event that any scheduled Interest
Payment Date or the Maturity Date for the Notes falls on a day that is not a Business Day, then payment of interest payable on such Interest Payment Date or of principal and interest payable on the Maturity Date will be paid on the next succeeding
day which is a Business Day (any payment made on such date will be treated as being made on the date that the payment was first due and no interest on such payment will accrue for the period from and after such scheduled Interest Payment Date);
provided, that in the event that any scheduled Floating Rate Interest Payment Date falls on a day that is not a Business Day and the next succeeding Business Day falls in the next succeeding calendar month, such Floating Rate Interest Payment Date
will be accelerated to the immediately preceding Business Day, and, in each such case, the amounts payable on such Business Day will include interest accrued to, but excluding, such Business Day. Dollar amounts resulting from interest calculations
will be rounded to the nearest cent, with one-half cent being rounded upward. 

(d)    The Corporation shall take such actions as are necessary to ensure that from the commencement of the Floating Rate
Period for so long as any of the Notes remain outstanding there will at all times be a Calculation Agent appointed to calculate Three-Month Term SOFR in respect of each Floating Rate Period. The calculation of Three-Month Term SOFR for each
applicable Floating Rate Period by the Calculation Agent will (in the absence of manifest error) be final and binding. The Calculation Agent’s determination of any interest rate and its calculation of interest payments for any period will be
maintained on file at the Calculation Agent’s principal offices, will be made available to any Holder of the Notes upon request and will be provided to the Trustee. The Calculation Agent shall have all the rights, protections and indemnities
afforded to the Trustee under the Base Indenture and hereunder. The Calculation Agent may be removed by the Corporation at any time. If the Calculation Agent is unable or unwilling to act as Calculation Agent or is removed by the Corporation, the
Corporation will promptly appoint a replacement Calculation Agent. The Calculation Agent may not resign its duties without a successor having been duly appointed; provided, that if a successor Calculation Agent has not been appointed by the
Corporation and such successor accepted such position within 30 days after the giving of notice of resignation by the Calculation Agent, then the resigning Calculation Agent may petition, at the expense of the Corporation, any court of competent
jurisdiction for the appointment of a successor Calculation Agent with respect to such series. The Trustee shall not be under any duty to succeed to, assume or otherwise perform, any duties of the Calculation

  
 10 

 
Agent, or to appoint a successor or replacement in the event of the Calculation Agent’s resignation or removal or to replace the Calculation Agent in the event of a default, breach or
failure of performance on the part of the Calculation Agent with respect to the Calculation Agent’s duties and obligations hereunder. For the avoidance of doubt, if at any time there is no Calculation Agent appointed by the Corporation, then
the Corporation shall be the Calculation Agent. The Corporation may appoint itself or any of its Affiliates to be the Calculation Agent. 

(e)    Effect of Benchmark Transition Event. 

(1)    If the Calculation Agent determines that a Benchmark Transition Event and its related Benchmark Replacement Date
have occurred on or prior to the Reference Time in respect of any determination of the Benchmark on any date, then the Benchmark Replacement will replace the then-current Benchmark for all purposes relating to the Notes during the Floating Rate
Period in respect of such determination on such date and all determinations on all subsequent dates. In connection with the implementation of a Benchmark Replacement, the Calculation Agent will have the right to make Benchmark Replacement Conforming
Changes from time to time. 
 (2)    Notwithstanding anything set forth in Section 2.4(b) above, if the Calculation
Agent determines on or prior to the relevant Reference Time that a Benchmark Transition Event and its related Benchmark Replacement Date have occurred with respect to Three-Month Term SOFR, then the provisions set forth in this Section 2.4(e)
will thereafter apply to all determinations of the interest rate on the Notes during the Floating Rate Period. After a Benchmark Transition Event and its related Benchmark Replacement Date have occurred, the interest rate on the Notes for each
interest period during the Floating Rate Period will be an annual rate equal to the Benchmark Replacement plus 270 basis points. 

(3)    The Calculation Agent is expressly authorized to make certain determinations, decisions and elections under the
terms of the Notes, including with respect to the use of Three-Month Term SOFR as the Benchmark and under this Section 2.4(e). Any determination, decision or election that may be made by the Calculation Agent under the terms of the Notes,
including any determination with respect to a tenor, rate or adjustment or of the occurrence or non-occurrence of an event, circumstance or date and any decision to take or refrain from taking any action or
selection (A) will be conclusive and binding on the Holders of the Notes and the Trustee absent manifest error, (B) if made by the Corporation as Calculation Agent, will be made in the Corporation’s sole discretion, (C) if made
by a Calculation Agent other than the Corporation, will be made after consultation with the Corporation, and the Calculation Agent will not make any such determination, decision or election to which 

  
 11 

 
the Corporation reasonably objects and (D) notwithstanding anything to the contrary herein or in the Base Indenture, shall become effective without consent from the Holders of the Notes, the
Trustee or any other party. If the Calculation Agent fails to make any determination, decision or election that it is required to make under the terms of the Notes, then the Corporation will make such determination, decision or election on the same
basis as described above. 
 (4)    The Corporation (or its Calculation Agent) shall notify the Trustee in writing
(i) upon the occurrence of the Benchmark Transition Event or the Benchmark Replacement Date, and (ii) of any Benchmark Replacements, Benchmark Replacement Conforming Changes and other items affecting the interest rate on the Notes after a
Benchmark Transition Event. 
 (5)    The Trustee (including in its capacity as Paying Agent) shall have no
(i) responsibility or liability for the (A) Three-Month Term SOFR Conventions, (B) selection of an alternative reference rate to Three-Month Term SOFR (including, without limitation, whether the conditions for the designation of such
rate have been satisfied or whether such rate is a Benchmark Replacement or an Unadjusted Benchmark Replacement), (C) determination or calculation of a Benchmark Replacement, or (D) determination of whether a Benchmark Transition Event or
Benchmark Replacement Date has occurred, and in each such case under clauses (A) through (D) above shall be entitled to conclusively rely upon the selection, determination, and/or calculation thereof as provided by the Corporation or its
Calculation Agent, as applicable, and (ii) liability for any failure or delay in performing its duties hereunder as a result of the unavailability of a Benchmark rate as described in the definition thereof, including, without limitation, as a
result of the Corporation’s or Calculation Agent’s failure to select a Benchmark Replacement or the Calculation Agent’s failure to calculate a Benchmark. The Trustee shall be entitled to rely conclusively on all notices from the
Corporation or its Calculation Agent regarding any Benchmark or Benchmark Replacement, including, without limitation, in regards to Three-Month Term SOFR Conventions, a Benchmark Transition Event, Benchmark Replacement Date, and Benchmark
Replacement Conforming Changes. The Trustee shall not be responsible or liable for the actions or omissions of the Calculation Agent, or any failure or delay in the performance of the Calculation Agent’s duties or obligations, nor shall it be
under any obligation to monitor or oversee the performance of the Calculation Agent. The Trustee shall be entitled to conclusively rely on any determination made, and any instruction, notice, Officers’ Certificate or other instruction or
information provided by the Calculation Agent without independent verification, investigation or inquiry of any kind. The Trustee shall not be obligated to enter into any amendment or supplement hereto that adversely impacts its rights, duties,

  
 12 

 
obligations, immunities or liabilities (including, without limitation, in connection with the adoption of any Benchmark Replacement Conforming Changes). 

(6)    If the then-current Benchmark is Three-Month Term SOFR, the Calculation Agent will have the right to establish the
Three-Month Term SOFR Conventions, and if any of the foregoing provisions concerning the calculation of the interest rate and the payment of interest during the Floating Rate Period are inconsistent with any of the Three-Month Term SOFR Conventions
determined by the Calculation Agent, then the relevant Three-Month Term SOFR Conventions will apply. 
 Section 2.5 Redemption.

 (a)    The Notes shall be redeemable, in each case, in whole or in part from time to time, at the option of the
Corporation beginning with the Interest Payment Date on March 15, 2030, but not prior thereto (except upon the occurrence of certain events specified below), and on any Interest Payment Date thereafter (each, a “Redemption
Date”), subject to obtaining the prior approval of the Federal Reserve to the extent such approval is then required under the rules of the Federal Reserve. The Notes may not otherwise be redeemed prior to the Maturity Date, except that the
Corporation may, at its option, redeem the Notes before the Maturity Date, in whole, but not in part, subject to obtaining the prior approval of the Federal Reserve to the extent such approval is then required under the rules of the Federal Reserve,
upon the occurrence of a Tier 2 Capital Event or a Tax Event, or if the Corporation is required to register as an investment company pursuant to the Investment Company Act of 1940, as amended (15 U.S.C. 80a-1
et seq.). Any such redemption will be at a Redemption Price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the Redemption Date fixed by the Corporation. The provisions of
Article XI of the Base Indenture shall apply to any redemption of the Notes pursuant to this Section 2.5. Any partial redemption will be made in accordance with DTC’s applicable procedures among all of the Holders of the Notes. If any Note
is to be redeemed in part only, the notice of redemption relating to such Note shall state that it is a partial redemption and the portion of the principal amount thereof to be redeemed, and a replacement Note in principal amount equal to the
unredeemed portion thereof will be issued in the name of the Holder thereof upon cancellation of the original Note. The Notes are not subject to redemption or prepayment at the option of the Holders. 

Any notice of redemption may be conditional in the Corporation’s discretion on one or more conditions precedent, and the Redemption Date
may be delayed until such time as any or all of such conditions have been satisfied or revoked by the Corporation if it determines that such conditions will not be satisfied. 

Section 2.6 No Repayment or Sinking Fund. The Notes will not be subject to redemption or repayment at the option of any Holder at
any time prior to the Stated Maturity. No sinking fund will be provided with respect to the Notes. 

  
 13 

 Section 2.7 Notes Not Convertible or Exchangeable. The Notes will not be
convertible or exchangeable for other securities or property. 
 Section 2.8 Issuance of Notes; Selection of Depository. The
Notes shall be issued as Global Securities in permanent global form, without coupons. The initial Depositary for the Notes shall be DTC. 

Section 2.9 Further Issuances. The Corporation may, without consent of the Holders of the Notes but in compliance with the terms
of the Indenture, increase the principal amount of the Notes by issuing additional Notes on the same terms and conditions as the Notes, except for any differences in the issue price and interest accrued prior to the date of issuance of the
additional Notes, and with the same CUSIP number as the Notes; provided that such additional Notes are fungible with the Notes for U.S. federal income tax purposes. The Notes and any additional Notes issued by the Corporation will rank equally and
ratably and shall be treated as a single series of Securities for all purposes under the Indenture. 
 Section 2.10 No Additional
Amounts. In the event that any payment on the Notes is subject to withholding of any U.S. federal income tax or other tax or assessment (as a result of a change in law or otherwise), the Corporation will not pay additional amounts with respect
to such tax or assessment. 
 ARTICLE THREE 

APPOINTMENT OF THE TRUSTEE FOR THE NOTES 

Section 3.1 Security Registrar; Paying Agent. The Corporation appoints Wilmington Trust, National Association as Security
Registrar and Paying Agent with respect to the Notes, and the Trustee hereby accepts such appointment. 
 ARTICLE FOUR 

DEFEASANCE 

Section 4.1 Defeasance Applicable to Notes. Pursuant to Section 301(14) and Section 1301 of the Base Indenture,
provision is hereby made for both (i) defeasance of the Notes under Section 1302 of the Base Indenture and (ii) covenant defeasance of the Notes under Section 1303, in each case, upon the terms and conditions contained in Article
XIII of the Base Indenture. 

  
 14 

 ARTICLE FIVE 

MISCELLANEOUS 

Section 5.1 Application of Supplemental Indenture. Each and every term and condition contained in this Supplemental Indenture that
modifies, amends or supplements the terms and conditions of the Base Indenture shall apply only to the Notes created hereby and not to any future series of Securities established under the Base Indenture. 

Section 5.2 Benefits of this Supplemental Indenture. Nothing contained in this Supplemental Indenture or in the Notes, express or
implied, shall give to any Person, other than the parties to the Indenture, any Security Registrar, any Paying Agent, any Authenticating Agent and their successors under the Indenture, and the Holders, any benefit or any legal or equitable right,
remedy or claim under the Base Indenture or this Supplemental Indenture. 
 Section 5.3 Modification of the Base Indenture.
Except as expressly provided by this Supplemental Indenture, the provisions of the Base Indenture shall govern the terms and conditions of the Notes. 

Section 5.4 Effective Date. This Supplemental Indenture shall be effective as of the date first above written and upon the
execution and delivery hereof by each of the parties hereto. 
 Section 5.5 Counterparts. This Supplemental Indenture may be
executed in any number of counterparts, each of which so executed shall be deemed to be an original, but all such counterparts shall together constitute but one and the same instrument. 

Section 5.6 Successors and Assigns. All covenants and agreements in the Indenture, as supplemented and amended by this
Supplemental Indenture, by the Corporation will bind its successors and assigns, whether so expressed or not. 
 Section 5.7 Effect
of Headings. The Article and Section headings in this Supplemental Indenture are for convenience only and shall not affect the construction hereof. 

Section 5.8 Separability Clause. In case any provision in this Supplemental Indenture or in the Notes shall be invalid, illegal or
unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 

Section 5.9 Satisfaction and Discharge. The Corporation shall be deemed to have satisfied all of its obligations under this
Supplemental Indenture upon compliance with the provisions of Section 1302 of the Indenture relating to defeasance of the Notes, to the extent set forth in Section 1301. 

  
 15 

 Section 5.10 Ratification of the Base Indenture. The Base Indenture as
supplemented by this Supplemental Indenture, is in all respects ratified and confirmed, and this Supplemental Indenture will be deemed part of the Indenture in the manner and to the extent herein and therein provided. 

Section 5.11 Governing Law. This Supplemental Indenture and the Notes shall be governed by, and construed in accordance with,
the laws of the State of New York. 
 Section 5.12 Trustee Disclaimer. The Trustee accepts the amendments of the Base
Indenture effected by this Supplemental Indenture, but on the terms and conditions set forth in the Base Indenture, including the terms and provisions defining and limiting the liabilities and responsibilities of the Trustee. Without limiting the
generality of the foregoing, the Trustee shall not be responsible in any manner whatsoever for or with respect to (i) any of the recitals contained herein, all of which recitals are made solely by the Corporation, (ii) the proper
authorization hereof by the Corporation by action or otherwise, (iii) the due execution hereof by the Corporation or (iv) the consequences of any amendment herein provided for. 

  
 16 

 IN WITNESS WHEREOF, the parties hereto have caused this Third Supplemental Indenture to be duly executed by
their respective officers hereunto duly authorized, all as of the day and year first above written. 
  

			
	FULTON FINANCIAL CORPORATION
		
	By:	 	 /s/ Mark R. McCollom

	Name:	 	Mark R. McCollom
	Title:	 	Senior Executive Vice President
and Chief Financial Officer

  

			
	Attest:	 	 /s/ Daniel R. Stolzer

	Name:	 	Daniel R. Stolzer
	Title:	 	Senior Executive Vice President
		 	and Chief Legal Officer

  

			
	WILMINGTON TRUST, NATIONAL ASSOCIATION,
as Trustee
		
	By:	 	 /s/ Michael H. Wass

	Name:	 	Michael H. Wass
	Title:	 	Vice President

 EXHIBIT A 

FORM OF FACE OF 3.750% FIXED-TO-FLOATING RATE SUBORDINATED
NOTES DUE 2035 
 THE FOLLOWING LEGEND SHALL APPEAR ON THE FACE OF EACH GLOBAL SECURITY: 

THIS SECURITY IS AN UNSECURED SUBORDINATED DEBT OBLIGATION OF FULTON FINANCIAL CORPORATION. THIS SECURITY IS NOT A DEPOSIT OR SAVINGS ACCOUNT
AND IS NOT INSURED BY THE FEDERAL DEPOSIT INSURANCE CORPORATION OR ANY OTHER GOVERNMENTAL AGENCY OR INSTRUMENTALITY. 
 THIS SECURITY IS A
GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. THIS SECURITY MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A SECURITY REGISTERED, AND NO TRANSFER OF THIS
SECURITY IN WHOLE OR IN PART MAY BE REGISTERED, IN THE NAME OF ANY PERSON OTHER THAN SUCH DEPOSITARY OR A NOMINEE THEREOF, EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE. 

  
 A-1 

 FULTON FINANCIAL CORPORATION 

3.750% FIXED-TO-FLOATING RATE SUBORDINATED NOTES DUE 2035 

 

					
	No.     	 		  	U.S.$                     

 CUSIP NO. 360271 AM2 
 ISIN NO.
US360271AM20 
 FULTON FINANCIAL CORPORATION, a corporation duly organized and existing under the laws of the Commonwealth of Pennsylvania
(herein called the “Corporation,” which term includes any successor Person under the Indenture hereinafter referred to), for value received, hereby promises to pay
to                 , or registered assigns, the principal sum of                  Dollars
on March 15, 2035 (such date is hereinafter referred to as the “Stated Maturity Date”), unless redeemed prior to such date, and to pay interest thereon (i) from, and including, March 3, 2020, to, but excluding,
March 15, 2030, unless redeemed prior to such date, at a rate of 3.750% per annum, semi-annually in arrears on March 15 and September 15 of each year, commencing September 15, 2020 (each such date, a “Fixed Rate Interest
Payment Date,” with the period from, and including, March 3, 2020 to, but excluding, the first Fixed Rate Interest Payment Date and each successive period from, and including, a Fixed Rate Interest Payment Date to, but excluding, the next
Fixed Rate Interest Payment Date being a “Fixed Rate Period”) and (ii) from, and including, March 15, 2030 to, but excluding, the Stated Maturity Date, unless redeemed subsequent to March 15, 2030 but prior to the Stated
Maturity Date, at a rate equal to Three-Month Term SOFR, reset quarterly, plus 270 basis points, or such other rate as determined pursuant to the Supplemental Indenture, payable quarterly in arrears on March 15, June 15, September 15
and December 15 of each year through the Stated Maturity Date or earlier Redemption Date (each, a “Floating Rate Interest Payment Date” and, together with the Fixed Rate Interest Payment Dates, the “Interest Payment Dates,”
with the period from, and including, March 15, 2030 to, but excluding, the first Floating Rate Interest Payment Date and each successive period from, and including a Floating Rate Interest Payment Date to, but excluding, the next Floating Rate
Interest Payment Date being a “Floating Rate Period”). The amount of interest payable on any Fixed Rate Interest Payment Date during the Fixed Rate Period will be computed on the basis of a 360-day
year consisting of twelve 30-day months up to, but excluding March 15, 2030, and, the amount of interest payable on any Floating Rate Interest Payment Date during the Floating Rate Period will be computed
on the basis of a 360-day year and the number of days actually elapsed. In the event that any scheduled Interest Payment Date for this Security falls on a day that is not a Business Day, then payment of
interest payable on such Interest Payment Date will be paid on the next succeeding day which is a Business Day (any payment made on such date will be treated as being made on the date that the payment was first due and no interest on such payment
will accrue for the period from and after such scheduled Interest Payment Date); provided, that in the event that any scheduled Floating Rate Interest Payment Date falls on a day that is not a Business Day and the next succeeding Business Day falls
in the next succeeding calendar month, such Floating Rate Interest Payment Date will be accelerated to the immediately preceding Business Day, and, in each such case, the amounts payable on such Business Day will include interest accrued to, but
excluding, such Business Day. All percentages 

  
 A-2 

 
used in or resulting from any calculation of Three-Month Term SOFR shall be rounded, if necessary, to the nearest one hundred-thousandth of a percentage point, with 0.000005% rounded up to
0.00001%. 
 The interest so payable, and punctually paid or duly provided for, on any Interest Payment Date will, as provided in such
Indenture, be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on the fifteenth day (whether or not a Business Day) immediately preceding the applicable Interest Payment
Date. Any such interest not so punctually paid or duly provided for will forthwith cease to be payable to the Holder on such Regular Record Date and may either be paid to the Person in whose name this Security (or one or more Predecessor Securities)
is registered at the close of business on a Special Record Date for the payment of such Defaulted Interest to be fixed by the Corporation, notice whereof shall be given to Holders of Securities of this series not less than 10 days prior to such
Special Record Date, or be paid at any time in any other lawful manner not inconsistent with the requirements of any securities exchange on which the Securities of this series may be listed, and upon such notice as may be required by such exchange,
all as more fully provided in said Indenture. 
 Payment of the principal of (and premium, if any) and interest on this Security will be
made at the corporate trust office of the Trustee or at the office of any paying agent that the Corporation may designate, in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and
private debts. 
 Reference is hereby made to the further provisions of this Security set forth on the reverse hereof, which further
provisions shall for all purposes have the same effect as if set forth at this place. 
 Unless the certificate of authentication hereon has
been executed by the Trustee referred to on the reverse hereof by manual signature, this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. 

IN WITNESS WHEREOF, the Corporation has caused this instrument to be duly executed. 

[Signature Page Follows] 

  
 A-3 

									
		 		 		 	FULTON FINANCIAL CORPORATION
					
	Dated:	 		 		 		 	
					
		 		 		 	By:	 	  

		 		 		 	Name:	 	Mark R. McCollom
		 		 		 	Title:	 	Senior Executive Vice President and
		 		 		 		 	Chief Financial Officer

  

			
	Attest:	 	  

	Name:	 	Daniel R. Stolzer
	Title:	 	Senior Executive Vice President
		 	and Chief Legal Officer

 (Trustee’s Certificate of Authentication) 

This is one of the Securities of the series designated therein referred to in the within-mentioned Indenture. 

 

									
		 		 		 	WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee
					
	Dated:	 	
                    

	 		 	By:	 	
                    

		 		 		 		 	Authorized Officer

  
 A-4 

 [FORM OF REVERSE SIDE OF THE NOTE] 

This Security is one of a duly authorized issue of securities of the Corporation (herein called the “Securities”), issued and to be
issued in one or more series under an Indenture, dated as of March 3, 2020 (herein called the “Indenture,” which term shall have the meaning assigned to it in such instrument), between the Corporation and Wilmington Trust, National
Association, as Trustee (herein called the “Trustee”, which term includes any successor trustee under the Indenture), and reference is hereby made to the Indenture and all indentures supplemental thereto for a statement of the respective
rights, limitations of rights, duties and immunities thereunder of the Corporation, the Trustee, the holders of Senior Indebtedness and the Holders of the Securities and of the terms upon which the Securities are, and are to be, authenticated and
delivered. This Security is one of the series designated on the face hereof. 
 The indebtedness evidenced by this Security is, to the
extent provided in the Indenture, subordinate and subject in right of payment to the prior payment in full of all Senior Indebtedness, and this Security is issued subject to the provisions of the Indenture with respect thereto. Each Holder of this
Security, by accepting the same, (a) agrees to and shall be bound by such provisions, (b) authorizes and directs the Trustee on his or her behalf to take such actions as may be necessary or appropriate to effectuate the subordination so
provided and (c) appoints the Trustee his or her attorney-in-fact for any and all such purposes. Each Holder hereof, by his or her acceptance hereof, waives all
notice of the acceptance of the subordination provisions contained herein and in the Indenture by each holder of Senior Indebtedness, whether now outstanding or hereafter created, incurred, assumed or guaranteed, and waives reliance by each such
holder upon said provisions. 
 The Indenture contains provisions for defeasance at any time of certain restrictive covenants and Events of
Default with respect to this Security, in each case upon compliance with certain conditions set forth in the Indenture. 
 If an Event of
Default with respect to Securities of this series shall occur and be continuing, the principal of the Securities of this series may be declared due and payable in the manner and with the effect provided in the Indenture. 

The Corporation may, at its option, redeem the Securities, in whole or in part, at a redemption price equal to 100% of the principal amount of
the Securities to be redeemed, plus accrued and unpaid interest (the “Redemption Price”) to, but excluding, the date of redemption (the “Redemption Date”), on any Interest Payment Date on or after March 15, 2030. The
Corporation may also, at its option, redeem the Securities before the Stated Maturity Date, in whole, but not in part, at any time, upon the occurrence of a Tier 2 Capital Event, a Tax Event or if the Corporation is required to register as an
investment company pursuant to the Investment Company Act of 1940, as amended. Any such redemption will be at a redemption price equal to the Redemption Price to, but excluding, the Redemption Date fixed by the Corporation. 

  
 A-5 

 Notwithstanding any of the foregoing, to the extent then required under or pursuant to
applicable regulations of the Federal Reserve, this Security may not be repaid prior to the Stated Maturity Date without the prior written consent of the Federal Reserve. In the event of redemption of this Security in part only, a new Security or
Securities of this series and of like tenor for the unredeemed portion hereof will be issued in the name of the Holder hereof upon the cancellation hereof. The provisions of Article XI of the Base Indenture and Section 2.5 of the Supplemental
Indenture shall apply to the redemption of any Securities by the Corporation. 
 In the event that any payment on the Securities is subject
to withholding of any U.S. federal income tax or other tax or assessment (as a result of a change in law or otherwise), the Corporation will not pay additional amounts with respect to such tax or assessment. 

The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the modification of the rights and obligations
of the Corporation and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by the Corporation and the Trustee with the consent of the Holders of 66 2/3% in principal amount of the Securities at
the time Outstanding of each series to be affected. The Indenture also contains provisions permitting the Holders of specified percentages in principal amount of the Securities of each series at the time Outstanding, on behalf of the Holders of all
Securities of such series, to waive compliance by the Corporation with certain provisions of the Indenture and certain past defaults under the Indenture and their consequences. Any such consent or waiver by the Holder of this Security shall be
conclusive and binding upon such Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not notation of such consent or waiver is
made upon this Security. 
 As provided in and subject to the provisions of the Indenture, the Holder of this Security shall not have the
right to institute any proceeding with respect to the Indenture or for the appointment of a receiver or trustee or for any other remedy thereunder, unless such Holder shall have previously given the Trustee written notice of a continuing Event of
Default with respect to the Securities of this series, the Holders of not less than 25% in principal amount of the Securities of this series at the time Outstanding shall have made written request to the Trustee to institute proceedings in respect
of such Event of Default and offered the Trustee indemnity satisfactory to it, and the Trustee shall not have received from the Holders of a majority in principal amount of Securities of this series at the time Outstanding a direction inconsistent
with such request, and shall have failed to institute any such proceeding, for 60 days after receipt of such notice, request and offer of indemnity. The foregoing shall not apply to any suit instituted by the Holder of this Security for the
enforcement of any payment of principal hereof or any premium or interest hereon on or after the respective due dates expressed herein. 

No reference herein to the Indenture and no provision of this Security or of the Indenture shall alter or impair the obligation of the
Corporation, which is absolute and unconditional, to pay the principal of and any premium and interest on this Security at the times, place and rate, and in the coin or currency, herein prescribed. 

  
 A-6 

 As provided in the Indenture and subject to certain limitations therein set forth, the
transfer of this Security is registrable in the Security Register, upon surrender of this Security for registration of transfer at the office or agency of the Corporation maintained under Section 1002 of the Indenture for such purpose, duly
endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Corporation and the Security Registrar duly executed by, the Holder hereof or his attorney duly authorized in writing, and thereupon one or more new
Securities of this series and of like tenor, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees. 

The Securities of this series are issuable only in registered form without coupons in denominations of $1,000 and integral multiples of $1,000
in excess thereof. As provided in the Indenture and subject to certain limitations therein set forth, Securities of this series are exchangeable for a like aggregate principal amount of Securities of this series and of like tenor of a different
authorized denomination, as requested by the Holder surrendering the same. 
 No service charge shall be made for any such registration of
transfer or exchange, but the Corporation may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith. 

Prior to due presentment of this Security for registration of transfer, the Corporation, the Trustee and any agent of the Corporation or the
Trustee may treat the Person in whose name this Security is registered as the owner hereof for all purposes, whether or not this Security be overdue, and neither the Corporation, the Trustee nor any such agent shall be affected by notice to the
contrary. 
 This Security shall be governed by and construed in accordance with the laws of the State of New York. 

All terms used in this Security which are defined in the Indenture shall have the meanings assigned to them in the Indenture. 

  
 A-7Exhibit 10.1

 

SEVERANCE AGREEMENT AND RELEASE

 

This Full
and Final General Release (referred to herein as "Agreement") is made and entered into by ANDREW JOHNS WILLIAMS ("Employee")
and MEDICINE MAN TECHNOLOGIES, INC. (MMT), a corporation duly organized under the laws of the state of Nevada and having
its principal place of business at 4880 Havana Street, Suite 201 South, Denver, Colorado 80239 (hereinafter referred to as the
"Employer" "MMT" or "the Company"). The parties to this Agreement are referred to collectively herein
as the "Parties."

 

RECITALS 

 

WHEREAS Employee has been employed by the
Company since December 3, 2018;

 

WHEREAS Employee and
the Company desire to mutually agree to terminate Employee's employment pursuant Section 5(a)(1) to Employee's April 23, 2019 Employment
Agreement;

 

WHEREAS Employee has
been a member of the Company's Board of Directors ("Board") since 2014;

 

WHEREAS Employee and
the Company desire to mutually agree to terminate Employee's service on the Company's Board of Directors;

 

WHEREAS the effective
date ("Effective Date") of this Agreement will commence immediately upon the expiration of the seven-day revocation period
described in Paragraph 18 below; and

 

AGREEMENT

 

NOW, THEREFORE,
for and in consideration of the premises, agreements, covenants and conditions contained herein, the adequacy and sufficiency of
which are hereby expressly acknowledged, Employee agrees as follows:

 

1.          SEPARATION AND ACCRUED WAGES

 

A.       Employee's
active employment with the Company ended on February 3, 2020 ("Separation Date"). On the Separation Date, the
Company paid Employee all accrued wages through the Separation Date, subject to standard payroll deductions and withholdings.
The Company will also reimburse Employee for all outstanding approved expenses made on behalf of the Company within ten days
of the execution of this Agreement. Prior to the execution of this Agreement, the Company will provide Employee with a
detailed expense report setting forth all of Employee's approved expenses for 2019. Employee agrees that upon receipt of his
final check, Employee has received all wages, bonus, and benefits owed to him by the Company. Employee will be placed on paid
administrative leave through the date that any one of the long form agreements are executed between Future Vision Ltd, Future
Vision 2020 LLC, or Medicine Man Longmont LLC, but no later than February 25, 2020 (the "Leave End Date"). Employee
will execute a letter of resignation from his employment at the Company, effective as of the Leave End Date. Employee will
execute the Second Severance Agreement and Release, attached hereto as Exhibit A within three business days of the Leave End
Date, but no earlier than the Leave End Date.

 

B.       Employee
will execute a letter of resignation from his role on the Board, effective as of the date of Employee's separation from the Company.

 

 

 

 

    	 	1	 

     

    

 

2.          PAYMENT AND TAX LIABILITY

 

A.       In consideration
for the covenants undertaken and releases given herein by Employee, and provided that Employee executes and does not revoke this
Agreement, is not in breach or default of this Agreement as of February 3, 2020 and has performed all of his obligations
under this Agreement, the Company agrees that it shall provide Employee with the following:

 

(i)       
12 months' pay, in the gross amount of Three Hundred Thousand Dollars ($300,000.00). The first One Hundred and Fifty Thousand
Dollars ($150,000.00) will be paid within 10 days of the Effective Date of this Agreement. This amount constitutes payment for
alleged non-economic compensatory damages and IRS Form 1099 will be issued for this amount, with this amount reported under Box
3, Other Income. The second One Hundred and Fifty Thousand Dollars ($150,000.00) will be paid in 26 equal disbursements pursuant
to the Company's regularly-scheduled payroll and subject to appropriate and required withholding (the "Payroll Payments").
The Payroll Payments will commence on the next regularly scheduled payday after the Leave End Date. In the event of a change in
control of the Company, any remaining balance of the second One Hundred and Fifty Thousand Dollars ($150,000.00) will be paid to
Employee immediately. A change in control of the Company will include: 1) a sale of all or substantially all of the assets of the
Company; 2) any merger, consolidation or acquisition of the Company with, by or into another corporation, entity or person; or
3) any change in the ownership of more than fifty percent (50%) of the voting capital stock of the Company in one or more related
transactions.

 

(ii)     
Payment of the gross amount of Twenty-Five Thousand Dollars ($25,000.00) (the "Bonus Payment"). The Bonus Payment
represents the remaining amount of the annual bonus awarded by the Board on December 5, 2019 pursuant to Section 2(c) to Employee's
April 23, 2019 Employment Agreement and is subject to appropriate and required withholding. The Bonus Payment will be paid within
10 days of the Effective Date of this Agreement.

 

(iii)   
Continuation of family health care coverage through the Company's current provider on the Company's regular and customary
payroll cycle at the Company's cost until and ending one year from the Effective Date of this Agreement. Alternatively, should
the Employee elect to continue health coverage under COBRA, the Company will cover the cost of the coverage until and ending one
year from the Effective Date of this Agreement.

 

(iv)   
Prior to the execution of this Agreement, the Company shall seek and obtain approval from its Board for the grant of the
stock options referenced herein. Subject to approval by the Board, the Company shall grant Employee the option to purchase three
hundred and fifty thousand (350,000) shares of the Company's common stock, which shall be exercisable on a cashless basis , which
shall vest immediately upon the Effective Date of this Agreement, subject to the terms and conditions set forth in a Stock Option
Agreement and the Company's 2017 Equity Incentive Plan (hereafter collectively referred to as the "Stock Option Agreements"),
which are set forth in Exhibit B and incorporated by reference herein. The Company will assist and cooperate with Employee to
remove restrictions from stock certificates preparing certificates for sale as necessary within a reasonable time period subject
to Employee's leak-out provisions (2.e.) in his Employment Agreement and any other legal or regulatory requirements.

 

 

 

 

    	 	2	 

     

    

 

(v) Prior
to the execution of this Agreement, the Company shall seek and obtain approval from its Board for the grant of the stock options
referenced herein. Subject to approval by the Board, if Employee remains in compliance with all material terms of this Agreement,
including but not limited to Paragraphs 9 and 10, through the one year anniversary of the Effective Date of this Agreement, the
Company shall grant Employee the option to purchase fifteen thousand (15,000) shares of the Company's common stock, which shall
be exercisable on a cashless basis Such stock option grants shall be subject to the terms and conditions set forth in the Stock
Option Agreements. The Company will assist and cooperate with Employee to remove restrictions from stock certificates preparing
certificates for sale as necessary within a reasonable time period subject to Employee's leak-out provisions (2.e.) in his Employment
Agreement and any other legal or regulatory requirements.

 

B.       Employee
shall incur any and all tax liability on the payment that is being provided by the Company, as outlined above.

 

This
consideration is over and above all wages due, and Employee agrees that he is not otherwise entitled to receive a severance sum
from the Company and that the severance sum is above and in addition to all wages owed to him. Employee further agrees that
the consideration set forth above constitutes the entire consideration provided to him under this Agreement and that he shall not
seek any further compensation or consideration (including additional stock options) from the Releasees (defined below) for claimed
damages, costs, or attorneys' fees in connection with any claim released here.

 

3.          GENERAL RELEASE

 

A.       Release
by Employee. In exchange for the payment described in Paragraph 2A and the other promises contained herein, Employee hereby forever
releases and discharges the Company, its affiliates, owners, predecessors, successors, parents, subsidiaries, divisions, heirs,
assigns, executives, present and former representatives, present and former employees, consultants, agents, insurers and attorneys
from any and all claims, federal or state actions, appeals, demands, causes of action, liabilities, damages, interest, attorneys'
fees and expenses whatsoever, whether in law or equity or otherwise, and whether known or unknown arising out of Employee's employment
with the Company and/or appointment to the Board.

 

All of the released entities described above are collectively
referred to as the "Releasees."

 

This release includes, but is not
limited to, all claims, demands, federal or state administrative actions, appeals, and causes of action arising out of or in any
way related to: (a) all federal, state, and local laws, including, without limitation, the following federal and state statutes,
as amended, and their corresponding regulations: the Americans with Disabilities Act Amendments Act of 2008 and any subsequent
amendments, the Civil Rights Act of 1991, the Civil Rights Acts of 1866 and 1871, 42 U.S.C. § 1981, 42 U.S.C. § 1983,
Title VII of the Civil Rights Act of 1964, the Age Discrimination in Employment Act of 1967 and any subsequent amendments, the
Fair Labor Standards Act, the Employee Retirement Income Security Act, the Americans with Disabilities Act of 1990, the Equal
Pay Act of 1963, the Family and Medical Leave Act of 1993 and any subsequent amendments, the National Labor Relations Act, the
Labor Management Relations Act, the Occupational Safety and Health Act of 1970, the Older Workers Benefit Protection Act of 1990,
the Rehabilitation Act of 1973t; and (b) any claim or action under the common law of the State of Colorado including but not limited
to, any claim for compensation, damages, tort, breach of express or implied employment contract, breach of duty of good faith,
discrimination, intentional interference with contractual relations, fraud, misrepresentation, outrageous conduct, slander, libel,
negligent and/or intentional infliction of emotional distress, violation of public policy, negligent supervision, assault, battery,
breach of contract, implied breach of good faith and fair dealing, promissory estoppel, wrongful discharge, harassment, or retaliation,
and for any other damages or injuries incurred on the job; and (c) any claim under the constitution of the United States or the
State of Colorado; in relation to Employee's employment or incurred as a result of loss of employment. However, nothing in this
Agreement including but not limited to the release of claims, proprietary information, confidentiality, and non-disparagement
provisions, prevent Employee from filing a charge or complaint with or from participating in an investigation or proceeding conducted
by the EEOC, NLRB or any other any federal, state or local agency charged with the enforcement of any laws, or from exercising
Employee's rights under Section 7 of the NLRA to engage in joint activity with other employees, although by signing this release
Employee is waiving rights to individual relief based on claims asserted in such a charge or complaint, except where such a waiver
of individual relief is prohibited.

 

 

 

    	 	3	 

     

    

 

B.       Released Claims. The claims, charges, causes of actions, appeals, demands, losses, damages, attorneys' fees, expenses,
costs and liabilities released in Paragraph 3A shall be referred to collectively herein as the "Released Claims."

 

C.       Release
by the Company. The Employer, and its affiliates, owners, predecessors, successors, parents, subsidiaries, divisions,
assigns, executives, and present and former representatives, including without limitation, the Company's Executive Leadership
Team, hereby releases and forever discharge Employee, his heirs, attorney and agents from any and all claims, liens, demands,
obligations or liabilities whatsoever, whether known or unknown or suspected to exist by the Company, which it had or may
have now against Employee arising out of Employee's employment with the Company and/or appointment to the Board.

 

4.          PROMISE NOT TO PROSECUTE

 

Employee further
agrees that he shall not, at any time hereafter, commence, maintain or prosecute any action, suit, proceeding, investigation,
complaint, claim, grievance or charge with any court, administrative agency, arbitrator or any other body or person, whether
Federal, State, contractual or otherwise, or aid or assist others in prosecuting such action, suit, proceeding,
investigation, complaint, claim, grievance or charge on their behalf, except in response to governmental agency or court
inquiries or as compelled by legal process, against the other, or any of them, based in whole or in part upon, or arising out
of or in an way connected with, any of the claims released or any of the matters referred to in this Agreement. Employee
further agrees to indemnify and hold the Releasees harmless from and against any and all claims, demands, causes of action,
damages or liability of any kind, including the cost of defense and reasonable attorneys' fees arising out of or in
connection with, any action, suit, proceeding, investigation, complaint, claim, grievance or charge commenced, maintained, or
prosecuted by them contrary to the terms of this Agreement.

 

5.          RELEASE INCLUDES UNKNOWN CLAIMS

 

A.       The Parties understand and agree that the Released Claims are intended to and do include any and all claims of every nature and kind whatsoever, whether known, unknown, suspected, or unsuspected.

 

B.       The Parties further acknowledge that they may hereafter discover facts different from or in addition to those that they now know or believe to be true with respect to the Released Claims and agree that, in such
event, this Agreement shall nevertheless be and remain effective in all respects, notwithstanding such different or additional
facts, or the discovery thereof.

 

 

 

 

    	 	4	 

     

    

 

C.       The Parties represent and acknowledge (i) that they have conducted whatever investigation was deemed necessary to ascertain all facts and matters related to this Release; (ii) that they have had the opportunity
to consult with and to receive advice from legal counsel concerning this Release; and (iii) that they are not relying in any way
on any statement or representation by the other party or that party's attorneys, except as expressly stated herein, in reaching
his decision to enter into this Agreement.

 

6.          NO ASSIGNMENT OR TRANSFER OF RELEASED CLAIMS

 

The Parties represent
and warrant that they have not assigned, transferred, or hypothecated, or purported to assign, transfer, or hypothecate, to any
person, firm, corporation, association, or entity whatsoever any of the Released Claims.

 

7.          NO ADMISSION OF LIABILITY

 

Employee understands
and agrees that this Agreement is a release of disputed claims and does not constitute an admission of liability on the part of
the Company as to any matters whatsoever and that the Company merely intend by this Agreement to avoid further proceedings and
buy peace. The Company specifically denies liability for any harm allegedly suffered by Employee.

 

8.          RETURN OF PROPERTY AND RECORDS

 

Employee agrees
to return all of the Company's property immediately including keys, badges, cell phones, laptops and all other property belonging
to the Company that Employee has in his possession. Employee understands that he is not entitled to keep or preserve records of
the Company. This prohibition does not include any relevant employee files or records of Employee.

 

9.          CONFIDENTIALITY

 

A.       Employee
agrees he will keep this Agreement confidential, and that the Agreement and its terms and conditions, including the fact of
Release and the facts and circumstances underlying any potential claims, shall not be discussed with, or revealed to, any
person other than Employee's spouse, minor children, attorneys, accountants, or tax or financial advisors, except as
otherwise required by law or by order of a court as of February 3, 2020. Employee agrees that if he discusses or reveals the
terms or conditions of the Release to or with any of the aforementioned persons or entities, he will instruct those persons
or entities that the terms and conditions of the Agreement are confidential, and that such persons or entities shall be under
the same confidentiality obligations as to Employee and the Company. Employee understands and agrees that confidentiality is
a material provision of this Agreement. If Employee or his spouse or minor children take any action inconsistent with this
provision as of the date of signing this Agreement, the Payroll Payments will immediately be stopped and the Company will be
under no further obligation to continue the Payroll Payments.

 

 

 

 

    	 	5	 

     

    

 

B.       Company
agrees it will keep this Agreement confidential, and that the Agreement and its terms and conditions, including the fact of Release
and the facts and circumstances underlying any potential claims, shall not be discussed with, or revealed to, any person other
than Company's Board of Directors, attorneys, accountants, tax or financial advisors or those required for processing the payment
described above in Paragraph 2, except as otherwise required by law or by order of a court. Company agrees that if it discusses
or reveals the terms or conditions of the Release to or with any of the aforementioned persons or entities, it will instruct those
persons or entities that the terms and conditions of the Agreement are confidential, and that such persons or entities shall be
under the same confidentiality obligations as to Employee and the Company. Company understands and agrees that confidentiality
is a material provision of this Agreement.

 

10.          NON-DISPARAGEMENT

 

A.       Employee agrees not to make any statements to any third party that disparages the Company or other Releasees as of February 3, 2020. Nothing in the foregoing sentence, however, is intended to nor shall it be construed
to prevent Employee from making true statements to a third party pursuant to a valid subpoena or under oath and penalty of perjury
in a deposition or other court proceeding. Employee understands and agrees that non-disparagement is a material provision of this
Agreement. If Employee or his spouse or minor children take any action inconsistent with this provision as of the date of signing
this Agreement, the Payroll Payments will immediately be stopped and the Company will be under no further obligation to continue
the Payroll Payments.

 

B.       Company agrees that Justin Dye, Kim Townsend, Paula Upton, Raquel Fuentes, members of the Board of Directors, and members of the Company's Executive Leadership Team shall not make any statements to any
third party that disparages Employee. Nothing in the foregoing sentence, however, is intended to nor shall it be construed to prevent
Company from making true statements to a third party pursuant to a valid subpoena or under oath and penalty of perjury in a deposition
or other court proceeding. Company understands and agrees that non-disparagement is a material provision of this Agreement.

 

11.          COOPERATION

 

Employee agrees
to cooperate with the Company with respect to the prosecution and/or defense of legal claims which arose during Employee's
tenure as an employee of the Company, or which relate to events which occurred during Employee's tenure as an employee of the
Company or to which Employee has any information. Such cooperation shall include, but is not limited to, making himself
available for interview by the Company and/or its counsel, reviewing and/or identifying documents, giving truthful testimony
and/or testifying at trial, and further that Employee shall immediately notify the Company in writing if Employee is ever
subpoenaed or otherwise requested to testify in any matter involving the Company.

 

 

 

 

    	 	6	 

     

    

 

The Company
acknowledges that as a result of Employee's employment with the Company as Chief Executive Officer and as Co-Founder of the Company,
Employee has certain stock certificates with the Company. The Company agrees to cooperate with and provide assistance to Employee,
as necessary, in clearing and preparing for sale Employee's stock certificates with the Company, upon Employee's request and within
a reasonable time period subject to Employee's leak-out provisions (2.e.) in his Employment Agreement and any other legal or regulatory
requirements.

 

The Company
also acknowledges that as a result of Employee's employment with the Company as Chief Executive Officer and as Co-Founder of the
Company, Employee has assisted the Company regarding applications for certain licenses. Employee agrees to execute a voluntary
withdrawal of suitability application concurrently with his execution of this Agreement. Employee will not receive any additional
compensation for his execution of the voluntary withdrawal of suitability application. Following the Effective Date of this Agreement,
the Company agrees to compensate Employee at a rate of Four Hundred Dollars ($400.00) per hour (minimum of 2 (two) hours per request)
for any further assistance provided to Company. Company further agrees to reimburse Employees for all authorized costs incurred
by Employee in providing assistance to Company.

 

12.          NON-SOLICITATION/NON-COMPETE

 

Employee
agrees to continue to comply with the restrictive covenants contained in Paragraphs 8 and 9 of his Employment Agreement, executed
on April 23, 2019 ("Employment Agreement"), and understands that certain obligations in that agreement survive the termination
of his Employment Agreement and separation of his employment. Notwithstanding anything to the contrary in Employee's Employment
Agreement, the Company and Employee acknowledge and agree that Employee has prior and ongoing obligations to Medicine Man, MedPharm
Holdings and Future Vision. The Company acknowledges and agrees that Employee's ownership interest in and/or any assistance provided
to Medicine Man, MedPharm Holdings, Mx, LLC and Future Vision shall not be considered a violation of any of Employee's continuing
obligations to the Company, pursuant to the Employment Agreement.

 

The geographic
scope in Paragraph 8 of the Employment Agreement shall be limited to where the Company currently conducts business. In the event
the Company expands outside of the state of Colorado, it will provide notice to Employee and Employee will discontinue his involvement
in any competitive business for the remaining term of the restrictive period.

 

13.          PARTIES TO BEAR THEIR OWN COSTS

 

Employee understands
that he and the Company will each bear their own costs, expenses, and attorneys' fees, if any, in relation to this Agreement.

 

 

 

    	 	7	 

     

    

 

14.          REPRESENTATIONS

 

Each signatory
hereto warrants that s/he/it is legally competent and/or authorized to execute this Agreement and has not relied on any statements
or explanations in connection therewith. Moreover, each party hereby acknowledges that s/he/it has been afforded the opportunity
to be advised by legal counsel regarding the terms of this Agreement, including the release of all claims and waiver of rights.

 

15.          KNOWLEDGE, CAPACITY, AND AUTHORITY

 

Employee represents
and warrants that he had the opportunity to have counsel explain the contents of this Agreement to him. Employee represents that
he understands the contents of this Agreement and that he executed it knowingly and voluntarily and understands that after executing
it he cannot proceed against any Releasee on account of the matters referred to herein. Each party to this Agreement represents
and warrants that s/he/it has the authority and capacity to execute this Agreement.

 

16.          MODIFICATION

 

No provision of
this Release may be changed, altered, modified or waived except in writing signed by both Employee and the Company or other Releasees,
which writing shall specifically reference this Release and the provision that the parties intend to waive or modify.

 

17.          NON-WAIVER

 

No provision of
this Agreement may be waived unless in writing and signed by all the parties to this Agreement. Waiver of any one provision shall
not constitute waiver of any other provision. A delay of failure by either party to exercise a right under this Agreement, or a
partial or single exercise of that right, shall not constitute a waiver of that or any other right herein.

 

18.          SEVERABILITY

 

In the event any
provision of this Agreement should be held to be unenforceable, each and all of he other provisions of this Agreement shall remain
in full force and effect.

 

19.          WAIVER OF CLAIMS UNDER THE AGE
DISCRIMINATION IN EMPLOYMENT ACT

 

The Severance
Sum is intended in part as consideration for Employee's release and waiver of any and all claims under the ADEA. Employee
should consult with his attorneys about this release and waiver before executing this Agreement. Further, Employee has
twenty-one (21) calendar days from his receipt of this Agreement to consider the release and waiver of any and all claims
(including those arising under the ADEA), and, for a period of seven (7) calendar days following execution of the Agreement
by him, Employee may revoke this release and waiver in a writing received by counsel for the Company on or before the
expiration of the seven (7) calendar day period. This Agreement shall not become effective or enforceable until the seven (7)
calendar day revocation period set forth herein has expired without Employee having exercised his right of revocation (the
"Effective Date"). Notice should be sent in writing to the following: Daniel Pabon, Medicine Man Technologies, Inc.
4801 Havana Street, Suite 201, Denver, Colorado 80239.

 

 

 

 

    	 	8	 

     

    

 

20.          APPLICABLE LAW

 

This Agreement
shall be construed and enforced according to the laws of the State of Colorado

 

21.          RIGHTS AND REMEDIES UPON BREACH

 

If either
party breaches, or threatens to commit a breach of, any of the provisions of this Agreement, the Parties agree that the party against
whom the breach has been committed shall have the right and remedy to have each and every one of the covenants in this Agreement
specifically enforced and the right and remedy to obtain temporary and permanent injunctive relief, it being acknowledged and agreed
by the Parties that any breach or threatened breach of any of the covenants and agreements contained herein would cause irreparable
injury and that money damages would not provide an adequate remedy at law. In any proceeding seeking to enforce the terms of this
Agreement, the prevailing party shall be entitled to recover all reasonable attorneys' fees, costs and expenses, including any
expert fees, that were incurred by that party in connection with any such proceeding.

 

22.          COUNTERPARTS ACCEPTABLE

 

This Agreement
may be executed in two or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute
one and the same instrument.

 

23.          ENTIRE AGREEMENT

 

Employee
acknowledges that this Release constitutes a full, final, and complete settlement of the parties' differences and supersedes and
replaces any and all other written or oral exchanges, agreements, understandings, employment contracts, arrangements, or negotiations
between or among them relating to the subject matter hereof; and Employee affirmatively represents that there are no other prior
or contemporaneous exchanges, agreements, representations, arrangements, or understandings, written or oral, between or among the
parties relating to the subject matter hereof other than that as set forth herein, and that this Release contains the sole and
entire Release between them with respect to the subject matter hereof Employee further acknowledges and agrees that any language
proposed for, deleted from, or otherwise changed in any drafts of this Release but not included herein shall not be considered
in any way in the interpretation and application of this Release and shall not in any way affect the rights and obligations of
Employee, the Company, or Releasees.

 

 

 

 

 

    	 	9	 

     

    

 

PLEASE READ
CAREFULLY.

THIS AGREEMENT
INCLUDES A RELEASE OF ALL CLAIMS

KNOWN AND UNKNOWN.

 

I, ANDREW JOHNS WILLIAMS, ACKNOWLEDGE
THAT I HAVE READ THIS RELEASE, THAT I HAVE BEEN ADVISED TO CONSULT WITH AN ATTORNEY BEFORE EXECUTING THIS RELEASE, AND THAT I UNDERSTAND
ALL OF THIS AGREEMENT'S TERMS AND EXECUTE THE AGREEMENT VOLUNTARILY WITH FULL KNOWLEDGE OF ITS SIGNIFICANCE AND CONSEQUENCES. EMPLOYEE
ACKNOWLEDGES THAT HE HAD TWENTY ONE DAYS TO DECIDE IF HE WANTS TO SIGN THIS AGREEMENT.

 

IN WITNESS
WHEREOF, the Parties have executed this Agreement have set their hands the day and year set forth below their respective signatures.

 

 

	/s/ Andrew Johns Williams	 	Date:	2/23/2020
	Andrew Johns Williams	 		 
	 	 	 	 	 
	 	 	 	 	 
	Medicine Man Technologies, Inc.	 	 	 
	 	 	 	 	 
	/s/Justin Dye	 	Date:	2/25/2020
	By:	Justin Dye	 	 	 
	Title:	Chief Executive Officer	 	 	 

 

 

 

 

 

 

 

 

    	 	10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00305-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00305-of-00352.parquet"}]]